Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial.

In a Phase II ketamine trial for treatment-resistant depression (n = 63), NetraAI analyzed psychiatric scale data (175/patient) and MRI-derived features (185/patient).

NetraAI outperformed traditional machine learning (machine learning) models in predicting treatment outcomes, improving predictive accuracy by approximately 25-30% and achieving higher sensitivity and specificity in detecting responders.